Skip to main content
Top
Published in: Journal of Thrombosis and Thrombolysis 1/2018

01-01-2018

Heparin, coumarin, protein C, antithrombin, fibrinolysis and other clotting related resistances: old and new concepts in blood coagulation

Authors: A. Girolami, E. Cosi, S. Ferrari, B. Girolami

Published in: Journal of Thrombosis and Thrombolysis | Issue 1/2018

Login to get access

Abstract

The concept of resistance in blood coagulation has become important. In the past it was limited to the resistance shown by some patients to heparin, coumarin or aspirin. Subsequently, it was demonstrated that a mutation in a single clotting factor, FV, showed resistance to activated protein C. Since activated protein C is supposed to downregulate aFV and aFVIII, their persistence in the circulation gives origin to a hypercoagulable state. Recently antithrombin resistance has been defined. Several prothrombin abnormalities (dysprothrombinemias) have been shown to be resistant to the action of antithrombin. This is associated with the occurrence of a trombophilic state. Prothrombin may therefore be associated like FV with both a bleeding condition (prothrombin deficiency) and a thrombophilic state (some dysprothrombinemias). Finally, thrombomodulin resistance has been defined in liver cirrhosis. These patients often show an increased ratio between FVIII levels and protein C. This imbalance may be partly responsible for the frequent presence of portal vein thrombosis seen in these patients. All these studies have greatly increased the complexity of the clotting mechanisms and interactions. They have cast light on clinical events which had remained unknown or ill-defined.
Literature
2.
go back to reference Girolami A, Lazzarin M, Scarpa R (1969) Studio dell’antitrombina progressiva nell’ipotiroidismo. Progr Med 25:782–785 Girolami A, Lazzarin M, Scarpa R (1969) Studio dell’antitrombina progressiva nell’ipotiroidismo. Progr Med 25:782–785
3.
go back to reference King AB, O’Duffy AE, Kumar AB (2016) Heparin resistance and anticoagulation failure in a challenging case of cerebral venous sinus thrombosis. Neurohospitalist 6:118–121CrossRefPubMed King AB, O’Duffy AE, Kumar AB (2016) Heparin resistance and anticoagulation failure in a challenging case of cerebral venous sinus thrombosis. Neurohospitalist 6:118–121CrossRefPubMed
4.
go back to reference Van Bruwaene L, Huisman A, Urbanus RT, Versluys B (2016) Heparin-resistant thrombosis due to homozygous antithrombin deficiency treated with rivaroxaban: a case report. J Pediatr Hematol Oncol 38:658–660CrossRefPubMed Van Bruwaene L, Huisman A, Urbanus RT, Versluys B (2016) Heparin-resistant thrombosis due to homozygous antithrombin deficiency treated with rivaroxaban: a case report. J Pediatr Hematol Oncol 38:658–660CrossRefPubMed
5.
go back to reference Zheng H, Ma HP, Xu WF, Zhang YQ, Wu JJ, Wang J (2014) Identification of a new SERPINC1 mutation in a Kazak family that alters the heparin binding capacity of antithrombin. Thromb Res 134:1344–1349CrossRefPubMed Zheng H, Ma HP, Xu WF, Zhang YQ, Wu JJ, Wang J (2014) Identification of a new SERPINC1 mutation in a Kazak family that alters the heparin binding capacity of antithrombin. Thromb Res 134:1344–1349CrossRefPubMed
6.
go back to reference Oldenburg J, Müller CR, Rost S, Watzka M, Bevans CG (2014) Comparative genetics of warfarin resistance. Hamostaseologie 34:143–159CrossRefPubMed Oldenburg J, Müller CR, Rost S, Watzka M, Bevans CG (2014) Comparative genetics of warfarin resistance. Hamostaseologie 34:143–159CrossRefPubMed
7.
go back to reference Kim Y, Smith A, Wu AH (2013) C3435T polymorphism of MDR1 gene with warfarin resistance. Clin Chim Acta 425:34–36CrossRefPubMed Kim Y, Smith A, Wu AH (2013) C3435T polymorphism of MDR1 gene with warfarin resistance. Clin Chim Acta 425:34–36CrossRefPubMed
8.
go back to reference Lewis BC, Nair PC, Heran SS, Somogyi AA, Bowden JJ, Doogue MP, Miners JO (2016) Warfarin resistance associated with genetic polymorphism of VKORC1: linking clinical response to molecular mechanism using computational modeling. Pharmacogenet Genomics 26:44–50CrossRefPubMed Lewis BC, Nair PC, Heran SS, Somogyi AA, Bowden JJ, Doogue MP, Miners JO (2016) Warfarin resistance associated with genetic polymorphism of VKORC1: linking clinical response to molecular mechanism using computational modeling. Pharmacogenet Genomics 26:44–50CrossRefPubMed
9.
go back to reference O’Sullivan KE, Meany B, Hurley JP (2015) Warfarin resistance due to VKORC1 gene mutation in a patient following mechanical aortic valve replacement with an ON-X valve. Int J Cardiol 188:63–64CrossRef O’Sullivan KE, Meany B, Hurley JP (2015) Warfarin resistance due to VKORC1 gene mutation in a patient following mechanical aortic valve replacement with an ON-X valve. Int J Cardiol 188:63–64CrossRef
10.
go back to reference Dahlbäck B, Carlsson M, Svensson PJ (1993) Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C. Proc Natl Acad Sci USA 90:1004–1008CrossRefPubMedPubMedCentral Dahlbäck B, Carlsson M, Svensson PJ (1993) Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C. Proc Natl Acad Sci USA 90:1004–1008CrossRefPubMedPubMedCentral
11.
go back to reference Bertina RM, Koeleman BP, Koster T, Rosendaal FR, Dirven RJ, de Ronde H, van der Velden PA, Reitsma PH (1994) Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 369:64–67CrossRefPubMed Bertina RM, Koeleman BP, Koster T, Rosendaal FR, Dirven RJ, de Ronde H, van der Velden PA, Reitsma PH (1994) Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 369:64–67CrossRefPubMed
12.
go back to reference Girolami A, Simioni P, Scarano L, Girolami B, Marchiori A (1998) Hemorrhagic and thrombotic disorders due to factor V deficiencies and abnormalities: an updated classification. Blood Rev 12:45–51CrossRefPubMed Girolami A, Simioni P, Scarano L, Girolami B, Marchiori A (1998) Hemorrhagic and thrombotic disorders due to factor V deficiencies and abnormalities: an updated classification. Blood Rev 12:45–51CrossRefPubMed
13.
go back to reference Chan WP, Lee CK, Kwong YL, Lam CK, Liang R (1998) A novel mutation of Arg306 of factor V gene in Hong Kong Chinese. Blood 91:1135–1139PubMed Chan WP, Lee CK, Kwong YL, Lam CK, Liang R (1998) A novel mutation of Arg306 of factor V gene in Hong Kong Chinese. Blood 91:1135–1139PubMed
14.
go back to reference Williamson D, Brown K, Luddington R, Baglin C, Baglin T. Factor V (1998) Cambridge: a new mutation (Arg306ï→Thr) associated with resistance to activated protein C. Blood 91:1140–1144PubMed Williamson D, Brown K, Luddington R, Baglin C, Baglin T. Factor V (1998) Cambridge: a new mutation (Arg306ï→Thr) associated with resistance to activated protein C. Blood 91:1140–1144PubMed
15.
go back to reference Mumford AD, McVey JH, Morse CV, Gomez K, Steen M, Norstrom EA, Tuddenham EG, Dahlback B, Bolton-Maggs PH (2003) Factor V I359T: a novel mutation associated with thrombosis and resistance to activated protein C. Br J Haematol 123:496–501CrossRefPubMed Mumford AD, McVey JH, Morse CV, Gomez K, Steen M, Norstrom EA, Tuddenham EG, Dahlback B, Bolton-Maggs PH (2003) Factor V I359T: a novel mutation associated with thrombosis and resistance to activated protein C. Br J Haematol 123:496–501CrossRefPubMed
16.
go back to reference Zöller B, Berntsdotter A, García de Frutos P, Dahlbäck B (1995) Resistance to activated protein C as an additional genetic risk factor in hereditary deficiency of protein S. Blood 85:3518–3523PubMed Zöller B, Berntsdotter A, García de Frutos P, Dahlbäck B (1995) Resistance to activated protein C as an additional genetic risk factor in hereditary deficiency of protein S. Blood 85:3518–3523PubMed
17.
go back to reference Jenkins PV, Rawley O, Smith OP, O’Donnell JS (2012) Elevated factor VIII levels and risk of venous thrombosis. Br J Haematol 157:653–663CrossRefPubMed Jenkins PV, Rawley O, Smith OP, O’Donnell JS (2012) Elevated factor VIII levels and risk of venous thrombosis. Br J Haematol 157:653–663CrossRefPubMed
18.
19.
go back to reference Abheiden CNH, Fuijkschot WW, Arduç A, van Diemen JJK, Harmsze AM, de Boer MA, Thijs A, de Vries JIP (2017) Post-pregnancy aspirin resistance appears not to be related with recurrent hypertensive disorders of pregnancy. Eur J Obstet Gynecol Reprod Biol 210:139–143CrossRefPubMed Abheiden CNH, Fuijkschot WW, Arduç A, van Diemen JJK, Harmsze AM, de Boer MA, Thijs A, de Vries JIP (2017) Post-pregnancy aspirin resistance appears not to be related with recurrent hypertensive disorders of pregnancy. Eur J Obstet Gynecol Reprod Biol 210:139–143CrossRefPubMed
20.
go back to reference Macchi L, Sorel N, Christiaens L (2006) Aspirin resistance: definitions, mechanisms, prevalence, and clinical significance. Curr Pharm Des 12:251–258CrossRefPubMed Macchi L, Sorel N, Christiaens L (2006) Aspirin resistance: definitions, mechanisms, prevalence, and clinical significance. Curr Pharm Des 12:251–258CrossRefPubMed
21.
go back to reference Eskandarian R, Razavi M, Fattah A, Ghods K, Forozeshfard M (2017) Prevalence of aspirin resistance in patients with type II diabetes: a descriptive-analytical study. Int J Clin Pharmacol Ther 55(6):493–497CrossRefPubMed Eskandarian R, Razavi M, Fattah A, Ghods K, Forozeshfard M (2017) Prevalence of aspirin resistance in patients with type II diabetes: a descriptive-analytical study. Int J Clin Pharmacol Ther 55(6):493–497CrossRefPubMed
22.
go back to reference Violi F, Pignatelli P (2006) Aspirin resistance: is this term meaningful? Curr Opin Hematol 13:331–336CrossRefPubMed Violi F, Pignatelli P (2006) Aspirin resistance: is this term meaningful? Curr Opin Hematol 13:331–336CrossRefPubMed
23.
go back to reference Fuchigami S, Oshima S, Hokimoto S, Noda K, Fukushima H, Yoshida T, Takushi Y, Ogawa H (2006) Subacute thrombosis after coronary stenting occurring with resistance to ticlopidine. Intern Med 45:675–678CrossRefPubMed Fuchigami S, Oshima S, Hokimoto S, Noda K, Fukushima H, Yoshida T, Takushi Y, Ogawa H (2006) Subacute thrombosis after coronary stenting occurring with resistance to ticlopidine. Intern Med 45:675–678CrossRefPubMed
24.
go back to reference Matetzky S, Shenkman B, Guetta V, Shechter M, Beinart R, Goldenberg I, Novikov I, Pres H, Savion N, Varon D, Hod H (2004) Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. Circulation 109:3171–3175CrossRefPubMed Matetzky S, Shenkman B, Guetta V, Shechter M, Beinart R, Goldenberg I, Novikov I, Pres H, Savion N, Varon D, Hod H (2004) Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. Circulation 109:3171–3175CrossRefPubMed
25.
go back to reference Nguyen TA, Diodati JG, Pharand C (2005) Resistance to clopidogrel: a review of the evidence. J Am Coll Cardiol 45:1157–1164CrossRefPubMed Nguyen TA, Diodati JG, Pharand C (2005) Resistance to clopidogrel: a review of the evidence. J Am Coll Cardiol 45:1157–1164CrossRefPubMed
26.
go back to reference Girolami A, Scarano L, Saggiorato G, Girolami B, Bertomoro A, Marchiori A (1998) Congenital deficiencies and abnormalities of prothrombin. Blood Coagul Fibrinolysis 9:557–569CrossRefPubMed Girolami A, Scarano L, Saggiorato G, Girolami B, Bertomoro A, Marchiori A (1998) Congenital deficiencies and abnormalities of prothrombin. Blood Coagul Fibrinolysis 9:557–569CrossRefPubMed
27.
go back to reference Lancellotti S, Basso M, De Cristofaro R (2013) Congenital prothrombin deficiency: an update. Semin Thromb Hemost 39:596–606CrossRefPubMed Lancellotti S, Basso M, De Cristofaro R (2013) Congenital prothrombin deficiency: an update. Semin Thromb Hemost 39:596–606CrossRefPubMed
28.
go back to reference Girolami A, Candeo N, Vettore S, Lombardi AM, Girolami B (2010) The clinical significance of the lack of arterial or venous thrombosis in patients with congenital prothrombin or FX deficiency. J Thromb Thrombolysis 29:299–302CrossRefPubMed Girolami A, Candeo N, Vettore S, Lombardi AM, Girolami B (2010) The clinical significance of the lack of arterial or venous thrombosis in patients with congenital prothrombin or FX deficiency. J Thromb Thrombolysis 29:299–302CrossRefPubMed
29.
go back to reference Miyawaki Y, Suzuki A, Fujita J, Maki A, Okuyama E, Murata M, Takagi A, Murate T, Kunishima S, Sakai M, Okamoto K, Matsushita T, Naoe T, Saito H, Kojima T (2012) Thrombosis from a prothrombin mutation conveying antithrombin resistance. N Engl J Med 366:2390–2396CrossRefPubMed Miyawaki Y, Suzuki A, Fujita J, Maki A, Okuyama E, Murata M, Takagi A, Murate T, Kunishima S, Sakai M, Okamoto K, Matsushita T, Naoe T, Saito H, Kojima T (2012) Thrombosis from a prothrombin mutation conveying antithrombin resistance. N Engl J Med 366:2390–2396CrossRefPubMed
30.
go back to reference Djordjevic V, Kovac M, Miljic P, Murata M, Takagi A, Pruner I, Francuski D, Kojima T, Radojkovic D (2013) A novel prothrombin mutation in two families with prominent thrombophilia–the first cases of antithrombin resistance in a Caucasian population. J Thromb Haemost 11:1936–1939PubMed Djordjevic V, Kovac M, Miljic P, Murata M, Takagi A, Pruner I, Francuski D, Kojima T, Radojkovic D (2013) A novel prothrombin mutation in two families with prominent thrombophilia–the first cases of antithrombin resistance in a Caucasian population. J Thromb Haemost 11:1936–1939PubMed
31.
go back to reference Sivasundar S, Oommen AT, Prakash O, Baskaran S, Biswas R, Nair S, Mohan CG, Biswas L (2013) Molecular defect of ‘Prothrombin Amrita’: substitution of arginine by glutamine (Arg553 to Gln) near the Na(+) binding loop of prothrombin. Blood Cells Mol Dis 50:182–183CrossRefPubMed Sivasundar S, Oommen AT, Prakash O, Baskaran S, Biswas R, Nair S, Mohan CG, Biswas L (2013) Molecular defect of ‘Prothrombin Amrita’: substitution of arginine by glutamine (Arg553 to Gln) near the Na(+) binding loop of prothrombin. Blood Cells Mol Dis 50:182–183CrossRefPubMed
32.
go back to reference Bulato C, Radu CM, Campello E, Gavasso S, Spiezia L, Tormene D, Simioni P (2016) New prothrombin mutation (Arg596Trp, Prothrombin Padua 2) associated With venous thromboembolism. Arterioscler Thromb Vasc Biol 36:1022–1029CrossRefPubMed Bulato C, Radu CM, Campello E, Gavasso S, Spiezia L, Tormene D, Simioni P (2016) New prothrombin mutation (Arg596Trp, Prothrombin Padua 2) associated With venous thromboembolism. Arterioscler Thromb Vasc Biol 36:1022–1029CrossRefPubMed
33.
go back to reference Vincent LM, Tran S, Livaja R, Bensend TA, Milewicz DM, Dahlbäck B (2013) Coagulation factor V(A2440G) causes east Texas bleeding disorder via TFPIα. J Clin Invest 123:3777–3787CrossRefPubMedPubMedCentral Vincent LM, Tran S, Livaja R, Bensend TA, Milewicz DM, Dahlbäck B (2013) Coagulation factor V(A2440G) causes east Texas bleeding disorder via TFPIα. J Clin Invest 123:3777–3787CrossRefPubMedPubMedCentral
34.
go back to reference Cunha ML, Bakhtiari K, Peter J, Marquart JA, Meijers JC, Middeldorp S (2015) A novel mutation in the F5 gene (factor V Amsterdam) associated with bleeding independent of factor V procoagulant function. Blood 125:1822–1825CrossRefPubMed Cunha ML, Bakhtiari K, Peter J, Marquart JA, Meijers JC, Middeldorp S (2015) A novel mutation in the F5 gene (factor V Amsterdam) associated with bleeding independent of factor V procoagulant function. Blood 125:1822–1825CrossRefPubMed
35.
go back to reference Tardy-Poncet B, Piot M, Brunet D, Chapelle C, Bonardel M, Mismetti P, Morange P, Tardy B (2012) TFPI resistance related to inherited or acquired protein S deficiency. Thromb Res 130:925–928CrossRefPubMed Tardy-Poncet B, Piot M, Brunet D, Chapelle C, Bonardel M, Mismetti P, Morange P, Tardy B (2012) TFPI resistance related to inherited or acquired protein S deficiency. Thromb Res 130:925–928CrossRefPubMed
36.
go back to reference Faille D, Labreuche J, Meseguer E, Huisse MG, Ajzenberg N, Mazighi M (2014) Endothelial markers are associated with thrombolysis resistance in acute stroke patients. Eur J Neurol 21:643–647CrossRefPubMed Faille D, Labreuche J, Meseguer E, Huisse MG, Ajzenberg N, Mazighi M (2014) Endothelial markers are associated with thrombolysis resistance in acute stroke patients. Eur J Neurol 21:643–647CrossRefPubMed
37.
go back to reference Semeraro F, Incampo F, Ammollo CT, Dellanoce C, Paoletti O, Testa S, Colucci M (2016) Dabigatran but not rivaroxaban or apixaban treatment decreases fibrinolytic resistance in patients with atrial fibrillation. Thromb Res 138:22–29CrossRefPubMed Semeraro F, Incampo F, Ammollo CT, Dellanoce C, Paoletti O, Testa S, Colucci M (2016) Dabigatran but not rivaroxaban or apixaban treatment decreases fibrinolytic resistance in patients with atrial fibrillation. Thromb Res 138:22–29CrossRefPubMed
38.
go back to reference Hantgan RR, Jerome WG, Handt S (1998) Platelets and endothelial cells act in concert to delay thrombolysis–evidence from an in vitro model of the human occlusive thrombus. Thromb Haemost 79:602–608PubMed Hantgan RR, Jerome WG, Handt S (1998) Platelets and endothelial cells act in concert to delay thrombolysis–evidence from an in vitro model of the human occlusive thrombus. Thromb Haemost 79:602–608PubMed
40.
go back to reference La Mura V, Tripodi A, Tosetti G, Cavallaro F, Chantarangkul V, Colombo M, Primignani M (2016) Resistance to thrombomodulin is associated with de novo portal vein thrombosis and low survival in patients with cirrhosis. Liver Int 36:1322–1330CrossRefPubMed La Mura V, Tripodi A, Tosetti G, Cavallaro F, Chantarangkul V, Colombo M, Primignani M (2016) Resistance to thrombomodulin is associated with de novo portal vein thrombosis and low survival in patients with cirrhosis. Liver Int 36:1322–1330CrossRefPubMed
41.
go back to reference Sargento-Freitas J, Silva F, Pego J, Duque C, Cordeiro G, Cunha L (2014) Cardioembolic stroke in a patient taking Dabigatran Etexilate: the first case report of clinical and pharmacologic resistance. J Neurol Sci 346:348–349CrossRefPubMed Sargento-Freitas J, Silva F, Pego J, Duque C, Cordeiro G, Cunha L (2014) Cardioembolic stroke in a patient taking Dabigatran Etexilate: the first case report of clinical and pharmacologic resistance. J Neurol Sci 346:348–349CrossRefPubMed
42.
go back to reference Stewart RA, Astell H, Young L, White HD (2012) Thrombosis on a mechanical aortic valve whilst anti-coagulated with dabigatran. Heart Lung Circ 21:53–55CrossRefPubMed Stewart RA, Astell H, Young L, White HD (2012) Thrombosis on a mechanical aortic valve whilst anti-coagulated with dabigatran. Heart Lung Circ 21:53–55CrossRefPubMed
43.
go back to reference Simioni P, Tormene D, Tognin G, Gavasso S, Bulato C, Iacobelli NP, Finn JD, Spiezia L, Radu C, Arruda VR (2009) X-linked thrombophilia with a mutant factor IX (factor IX Padua). N Engl J Med 361:1671–1675CrossRefPubMed Simioni P, Tormene D, Tognin G, Gavasso S, Bulato C, Iacobelli NP, Finn JD, Spiezia L, Radu C, Arruda VR (2009) X-linked thrombophilia with a mutant factor IX (factor IX Padua). N Engl J Med 361:1671–1675CrossRefPubMed
Metadata
Title
Heparin, coumarin, protein C, antithrombin, fibrinolysis and other clotting related resistances: old and new concepts in blood coagulation
Authors
A. Girolami
E. Cosi
S. Ferrari
B. Girolami
Publication date
01-01-2018
Publisher
Springer US
Published in
Journal of Thrombosis and Thrombolysis / Issue 1/2018
Print ISSN: 0929-5305
Electronic ISSN: 1573-742X
DOI
https://doi.org/10.1007/s11239-017-1559-0

Other articles of this Issue 1/2018

Journal of Thrombosis and Thrombolysis 1/2018 Go to the issue